Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;6(11):881-7.
doi: 10.4161/hv.6.11.12849. Epub 2010 Nov 1.

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

Christopher J Gill  1 , Roger Baxter, Alessandra Anemona, Giuseppe Ciavarro, Peter Dull
Affiliations

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

Christopher J Gill et al. Hum Vaccin. 2010 Nov.

Abstract

The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or Menactra® (MCV4) (sanofi pasteur). The proportion of subjects with hSBA titers ≥8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.

Trial registration: ClinicalTrials.gov NCT00856297.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study population flow diagram.
Figure 2
Figure 2
Immune responses to MenACWY-CRM or MCV4 at 1 and 22 months post vaccination. *MenACWY-CRM noninferior to MCV4. **MenACWY-CRM statistically higher than MCV4. Percentage of participants with human SBA titers ≥8 at 1 month post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccinees, contrasted with immune status of age-matched unvaccinated controls. Human SBA Geometric Mean Titers at 1 month and 22 months post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccines, contrast with immune stats of age-matched unvaccinated controls. Rabbit SBA Geometric Mean Titers at 1 month and 22 months post vaccination with MenACWY-CRM or MCV4, contrasted with immune status of age-matched unvaccinated controls.
Figure 2
Figure 2
Immune responses to MenACWY-CRM or MCV4 at 1 and 22 months post vaccination. *MenACWY-CRM noninferior to MCV4. **MenACWY-CRM statistically higher than MCV4. Percentage of participants with human SBA titers ≥8 at 1 month post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccinees, contrasted with immune status of age-matched unvaccinated controls. Human SBA Geometric Mean Titers at 1 month and 22 months post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccines, contrast with immune stats of age-matched unvaccinated controls. Rabbit SBA Geometric Mean Titers at 1 month and 22 months post vaccination with MenACWY-CRM or MCV4, contrasted with immune status of age-matched unvaccinated controls.
Figure 2
Figure 2
Immune responses to MenACWY-CRM or MCV4 at 1 and 22 months post vaccination. *MenACWY-CRM noninferior to MCV4. **MenACWY-CRM statistically higher than MCV4. Percentage of participants with human SBA titers ≥8 at 1 month post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccinees, contrasted with immune status of age-matched unvaccinated controls. Human SBA Geometric Mean Titers at 1 month and 22 months post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccines, contrast with immune stats of age-matched unvaccinated controls. Rabbit SBA Geometric Mean Titers at 1 month and 22 months post vaccination with MenACWY-CRM or MCV4, contrasted with immune status of age-matched unvaccinated controls.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia and Neisseria meningitidis. Lancet. 2007;369:2196–2210. - PubMed
    1. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:1745–1752. - PubMed
    1. McVernon J, Mitchison NA, Moxon ER. T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect Dis. 2004;4:40–43. - PubMed
    1. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27:112–116. - PubMed
    1. Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine. 2009;27:117–125. - PMC - PubMed

Publication types

MeSH terms

Associated data